Recursion raises $200 M in follow‑on offering and receives $10 M Sanofi milestone while reporting trial updates
+1 new source since this summary was written
Recursion Pharmaceuticals announced an underwritten common‑stock offering that raised $200 million and lifted its cash balance to $561 million, extending its cash runway into 2029. The company also disclosed Phase 1b/2 data for REC‑4881 showing a 47 % median polyp‑burden reduction in FAP patients and Phase 1 data for REC‑1245 with two confirmed partial responses in endometrial cancer and one unconfirmed response in liver cancer. Sanofi exercised an option on a joint immunology candidate, triggering a $10 million milestone payment and bringing total upfront and milestone payments from Sanofi to $144 million. The optioned candidate is slated to enter Phase 1 trials in 2027.
Why it matters
The equity raise provides non‑dilutive cash to fund upcoming trials, extending liquidity through 2029 (the company says). The Sanofi milestone validates Recursion’s AI‑driven platform and adds revenue, while the trial data suggest early efficacy signals that could de‑risk the pipeline.
Key facts
- 1Recursion completed an underwritten common‑stock offering that raised $200 million. tradingview.com
- 2The offering increased cash on hand to $561 million and extended the cash runway into 2029. investing.com
- 3REC‑4881 Phase 1b/2 data showed a 47 % median reduction in polyp burden after 12 weeks. tradingview.com
- 4REC‑1245 Phase 1 data reported two confirmed partial responses in endometrial cancer and one unconfirmed response in liver cancer. tradingview.com
- 5Sanofi’s option triggered a $10 million milestone payment to Recursion. tradingview.com
- 6The milestone brings total upfront and milestone payments from Sanofi to $144 million. securities.io
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.